Aridis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARDS research report →
About the company
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin.
- CEO
- Vu L. Truong
- IPO
- 2018
- Employees
- 37
- HQ
- Los Gatos, CA, US
Price Chart
- Market Cap
- $4.46K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 164.69%
- ROIC
- 172.72%
- Revenue
- $0 · 0.00%
- Net Income
- $-30,749,000 · 27.27%
- EPS
- $-1.64 · 52.33%
- Op Income
- $-29,993,000
- FCF YoY
- -24.47%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -26.04
- Avg Volume
- 16.62K
Get TickerSpark's AI analysis on ARDS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 24 | Windham-Bannister Susan Richards | other | 200,000 |
| Jun 27, 24 | HAMILTON JOHN F | other | 200,000 |
| Jun 27, 24 | Jafri Hasan | other | 250,000 |
| Jun 24, 24 | Patzer Eric | buy | 714,286 |
| Jun 24, 24 | Truong Vu | buy | 714,286 |
| Sep 18, 23 | HAMILTON JOHN F | other | 15,000 |
| Sep 18, 23 | Windham-Bannister Susan Richards | other | 15,000 |
| Sep 18, 23 | Patzer Eric | other | 15,000 |
| Sep 18, 23 | Truong Vu | other | 30,000 |
| Sep 18, 23 | Jafri Hasan | other | 20,000 |
Our ARDS coverage
Recent articles, reports, and earnings notes.
No research on ARDS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARDS report →Similar companies
Peers in the same neighborhood.